Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 19/20 | 0.84 |
| ▸ | LIMK2 | P53671 | 18/20 | 0.84 |
| ▸ | TESK2 | Q96S53 | 6/20 | 0.79 |
| ▸ | TESK1 | Q15569 | 5/20 | 0.77 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616746 | 0.91 | LIMK1 (1.00) | LIMK1LIMK2TESK2TESK1MAPK14 | |
| SCHEMBL6000061 | 0.89 | LIMK1 (1.00) | LIMK1LIMK2TESK2TESK1MAPK14 | |
| SCHEMBL6001580 | 0.88 | LIMK1 (0.86) | LIMK1LIMK2TESK2TESK1MAPK14 | |
| SCHEMBL6002069 | 0.87 | LIMK1 (1.00) | LIMK1LIMK2TESK2TESK1MAPK14 | |
| SCHEMBL6001859 | 0.87 | LIMK1 (1.00) | LIMK1LIMK2TESK2TESK1MAPK14 | |
| SCHEMBL6001635 | 0.86 | LIMK1 (0.82) | LIMK1LIMK2TESK2TESK1MAPK14 | |
| SCHEMBL6001871 | 0.86 | LIMK1 (0.85) | LIMK1LIMK2TESK2TESK1MAPK14 | |
| SCHEMBL6001588 | 0.86 | LIMK1 (0.83) | LIMK1LIMK2TESK2TESK1MAPK14 | |
| SCHEMBL6001893 | 0.84 | LIMK1 (0.81) | LIMK1LIMK2TESK2TESK1 | |
| SCHEMBL1616956 | 0.83 | LIMK1 (0.80) | LIMK1LIMK2TESK2TESK1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923556-B2 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923556-B2 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100029649-A1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| US-20100029649-A1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| US-20060178388-A1 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029649-A1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | LIMK1, LIMK2, MAPK1 | LIMK1 1/4885LIMK2 2/4885TESK2 790/4885 |
| US-20060178388-A1 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | LIMK1, LIMK2, MAPK1 | LIMK1 1/4885LIMK2 2/4885TESK2 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.